Tune in as the IMF brings myeloma support group leaders and patients to the 65th annual meeting of the American Society of Hematology (ASH), an exciting convergence of 10,000 health care professionals from around the world. Start following the IMF ASH team members now on social media as they ramp up to share the latest clinical updates in myeloma research, therapies, and practice strategies via Twitter (#ASH23 and #IMFASH23), Facebook, blogs, and videos.

The IMF’s utmost concern is always focused on patient’s health. With this year’s ASH meeting being hybrid, the IMF provided the option to support group leaders to attend ASH in person or virtually. The #IMFASH23 leaders team will consist of eight leaders attending in person and six leaders attending virtually as indicated below their photos.

We thank these leaders for their care and commitment in sharing their experience with the global myeloma community. We encourage you to read and follow these leaders for their unique perspectives.

Social Media Team

Jack Aiello

Jack Aiello

Diagnosed with myeloma in 1995, Jack is strong proponent of patients participating in clinical trials so that, in the future, myeloma and other cancers will be known as curable diseases. He is a proud facilitator of the San Francisco Bay Area Myeloma Support Group.

Jack Aiello
Patient
(virtual)

Follow Jack on X:
@JackMAiello
Read Blog Posts

Sheri Baker

Sheri Baker

Since being diagnosed in 2011, Sheri had a desire to help other patients & caregivers. She started the Treasure Valley Multiple Myeloma support group in Boise, Idaho in 2017. Sheri will be attending the ASH Annual Meeting for the second time.

Sheri Baker
Patient
(in-person)

Follow Sheri on X:
@blondie1746
Read Blog Posts

Becky Bosley

Becky Bosley

Becky is the proud facilitator of the Mid Atlantic Myeloma Support and Information Group, based out of the Baltimore, Maryland area. Becky has spent her entire professional career as an oncology nurse, achieving her OCN certification in 2015, working as an inpatient oncology nurse, and most recently, serving as a Cellular Therapy and Transplant Nurse Coordinator at University of Maryland Medical Center. She is excited to attend ASH for the first time as a correspondent with the IMF.

Becky Bosley
Healthcare
(in-person)

Follow Becky on X:
@MidAtlanticMSG
Read Blog Posts

Barbara Davis

Barbara Davis

Barbara Davis
Patient
(virtual)

Follow Barbara on X:
@bkinoglu
Read Blog Posts

Jessie Daw

Jessie Daw

Jessie was diagnosed with smoldering multiple myeloma in 2016, after several frequent bouts of respiratory infections. She has considered clinical trials, but thus far, has stayed with a “watch and wait” approach. She is a co-founder and leader of  the Eastern South Dakota Multiple Myeloma Support Group. This is Jessie’s first time attending ASH.

Jessie Daw
Patient
(virtual)

Follow Jessie on X:
@Daw6Jessie
Read Blog Posts

Oya Gilbert

Oya Gilbert

Oya Gilbert
Patient
(in-person)

Follow Oya on X:
@grandgrizzo
Read Blog Posts

Linda Huguelet

Linda Huguelet

Diagnosed with multiple myeloma in April 2010 at the young age of 46, Linda Huguelet has been co-leading the Chattanooga Multiple Myeloma Networking group alongside her husband since February 2011. Excited to learn of the latest developments in myeloma care, Linda will be attending ASH for the eighth time with the IMF.

Linda Huguelet
Patient
(in-person)

Follow Linda on X:
@LindaMYELOMA
Read Blog Posts

Diane Hunter

Diane Hunter

Diane Hunter
Patient
(virtual)

Follow Diane on X:
@DianeHunterMM
Read Blog Posts

Teresa Miceli

Teresa Miceli

Ms. Miceli is a 28-year nurse veteran in the area of Blood and Marrow Transplantation. Her current role is that of a BMT RN Care Coordinator for the Adult Program at Mayo Clinic-Rochester, MN. Ms. Miceli is a charter member of the Nurse Leadership Board of the International Myeloma Foundation. She is the facilitator of the Multiple Myeloma Sharing Sessions in Rochester, MN, a support group for myeloma survivors and caregivers.

Teresa Miceli
Healthcare
(in-person)

Follow Teresa on X:
@IMFnurseMYELOMA
Read Blog Posts

Adrienne Moore

Adrienne Moore

Adrienne Moore
Patient
(virtual)

Follow Adrienne on X:
@AdrienneMM2020
Read Blog Posts

Michael Tuohy

Michael Tuohy

Michael Tuohy was diagnosed with multiple myeloma in 2000 when he was 36 years old. With two young children (ages 2 and 7) the focus was always on finding the best treatment options, and beating myeloma. His approach over the years has been to become empowered by learning as much as he could to have productive conversations with his doctors, and to then share his experience with others to help them along their own journey. 

Michael Tuohy
Patient
(in-person)

Follow Michael on X:
@IMFmikeMYELOMA
Read Blog Posts

Robin Tuohy

Robin Tuohy

Robin Tuohy became a passionate advocate in the myeloma world in 2000 when her husband, Michael was diagnosed. In 2005 she began working for the International Myeloma Foundation, and is now Vice President Support Groups. She leads the IMF’s Support Group team and oversees approximately 160 U.S. myeloma specific support groups. Robin and her husband, Michael also founded and co-lead the Connecticut Multiple Myeloma Fighters Information Group.

Robin Tuohy
Care Partner
(in-person)

Follow Robin on X:
@IMFSupport
Read Blog Posts

Jill Zitzewitz

Jill Zitzewitz

Jill Zitzewitz, PhD is an associate professor in academic medicine, where she has spent her career studying therapeutic development for protein misfolding diseases. Since being diagnosed with multiple myeloma in 2017, Jill has transitioned to a fully educational role, teaching medical and graduate students and using her experience with multiple myeloma to provide the patient perspective to our future doctors and scientists.

Jill Zitzewitz
Patient
(virtual)

Follow Jill on X:
@JillZitzewitz
Read Blog Posts

Join IMF Chief Medical Officer Dr. Joseph Mikhael and the ASH Support Group Leaders Team LIVE at ASH 2023!

 

IMF Chief Medical Officer Dr. Joseph Mikhael along with the ASH support group leader team go live to discuss key myeloma research takeaways from the 2023 American Society of Hematology meeting.

Big ASH Experience

To be honest, I started writing this on the third day of ASH, but quickly realized I was going to need to rewatch the sessions and then watch them again. It's taken me some time to decipher what all the random words I had scribbled down were, and to gather my...

Our Impact: Never Taken for Granted

Our primary focus at ASH as the Myeloma Voices team is to be just that. To bring the ASH experience and information learned to the greater Myeloma community, both locally, nationally, and globally. During ASH, we accomplish this in several ways: our Facebook Live with...

Myeloma Voices at ASH: Exhausted & Empowered!

In general, our days at ASH 2023 started with an early morning wake-up, partially due to my East Coast home and West Coast time zone, but I was awake every morning around 4AM. This gave me time to sip coffee, finalize my choices of what presentations to attend that...

Our Days at ASH: Preparing for the Myeloma Voices to Arrive in San Diego

My goal this year at ASH was to help the readers of our blogs feel like they were in San Diego with us at one of the largest hematology conferences in the world. For readers to feel the experience, not just read about the science, was important to me. During the...

Fight, Fight, Fight, Fight Myeloma!

I’ve been following the various trials and have been interested in the response rates and value of using a four-drug combination (a quadruplet) versus a triplet (a three-drug regimen). The last few years, we have been learning about the response rates, side-effect...

ASH 2023 – So Much Multiple Myeloma Information

The 65th American Society of Hematology (ASH) Annual Meeting & Exposition provided so much information that I wish I could have been in more than one place at a time. The conference statistics provided by the International Myeloma Working Group (IMWG) are...

Diversity, Equity, and Inclusion (DEI) in Providing Care for Multiple Myeloma Patients

The 65th American Society of Hematology (ASH) Annual Meeting & Exposition provided an increased number of abstract presentations from previous years on the topic of DEI and disparity. There is a need for clinical trial patient participation to be reflective of the...

Closing Thoughts . . . Your Voices Matter

I learned that your voice does matter after watching attendees ask questions — some simple, others not so much — but they were heard. I got overloaded with abstract presentations galore but absorbed the portion I needed most. I had conversations with scientists to...

Real-World Studies, Teclistamab, AI, and more!

The 65th American Society of Hematology (ASH) annual conference has come and gone. I look forward to this each year, and so much preparation is done by staff at the International Myeloma Foundation (IMF) to help our Support Group Leader (SGL) team be ready for the...

Wrap It Up!

To wrap up my #IMFASH23 experience, I’ll keep it simple and share with you this video that Teresa Miceli and I did at ASH discussing T-Cell redirecting therapy, CAR-T, bi-specifics and comparison of side effects of CAR-T to bi-specifics and different targets (did I...